Phase2Therapy announces changes in the board.
Joop van Lunteren will step down as a board member. His replacement will be Dimor Elbers, Associate Director at Lonza. We would like to express our gratitute for Joop’s invaluable contribution to Phase2Therapy and wish him all the best in his future endeavours.
Phase2Therapy welcomes Dimor Elbers as its new board member. Dimor Elbers is Associate Director at Lonza, one of the world’s leading suppliers to the Pharma&Biotech and Specialty Ingredient markets. At Lonza, Elbers represents Lonza’s Pharma&Biotech contract manufacturing in the Benelux, Israel & Russia for Biologics.
“The track record of radio-immunotherapy in radiation oncology has been modest due to its complexity,” mentions Elbers. “The P2T radio-immunotherapy project has combined key technical improvements to overcome historical bottlenecks and establish the next generation radio-immunotherapy with the right experts involved. Pharmaco-vigilance and patient safety are key drivers in the study and the project carries high potential for Personalized Medicine in oncology.”